Anti-HER2 antibody therapy using gene-transduced adipocytes for HER2-positive breast cancer-Reference-Cited by-同舟云学术

Anti-HER2 antibody therapy using gene-transduced adipocytes for HER2-positive breast cancer

Published:2020-03-02 Issue:3 Volume:180 Page:625-634
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Masuda Takahito,Fujimoto Hiroshi^ORCID,Teranaka Ryotaro,Kuroda Masayuki,Aoyagi Yasuyuki,Nagashima Takeshi,Sangai Takafumi,Takada Mamoru,Nakagawa Ayako,Kubota Yoshitaka,Yokote Koutaro,Ohtsuka Masayuki

Funder

Japan Society for the Promotion of Science

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-020-05581-x.pdf

Reference31 articles.

1. Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, Cutter D, Darby S, McGale P, Taylor C, Wang YC, Bergh J, Di Leo A, Albain K, Swain S, Piccart M, Pritchard K (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379(9814):432–444. https://doi.org/10.1016/s0140-6736(11)61625-5

2. Anan K, Mitsuyama S, Koga K, Tanabe R, Saimura M, Tanabe Y, Watanabe M, Suehara N, Matsunaga H, Nishihara K, Abe Y, Nakano T, Tamae K, Ono M, Toyoshima S (2010) Disparities in the survival improvement of recurrent breast cancer. Breast Cancer 17(1):48–55. https://doi.org/10.1007/s12282-009-0103-2

3. Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN (2004) Is breast cancer survival improving? Cancer 100(1):44–52. https://doi.org/10.1002/cncr.11859

4. Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, Castro G, Jr., Untch M, Smith I, Gianni L, Baselga J, Al-Sakaff N, Lauer S, McFadden E, Leyland-Jones B, Bell R, Dowsett M, Jackisch C, Herceptin Adjuvant Trial Study T (2017) 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet 389(10075):1195–1205. https://doi.org/10.1016/S0140-6736(16)32616-2

5. Gianni L, Eiermann W, Semiglazov V, Lluch A, Tjulandin S, Zambetti M, Moliterni A, Vazquez F, Byakhov MJ, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Magazzu D, Heinzmann D, Steinseifer J, Valagussa P, Baselga J (2014) Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol 15(6):640–647. https://doi.org/10.1016/s1470-2045(14)70080-4

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ex vivo dual gene therapy using human adipocytes secreting anti-HER2 antibody on HER2-positive xenograft tumor models;Breast Cancer;2023-08-23

2. Osteoporosis Associated with Breast Cancer Treatments Based on Types of Hormonal Therapy: A Cross-Sectional Study Using Korean National Sample Data;Medicina;2023-08-22

3. Antibody-Dependent Cell-Mediated Cytotoxicity Through Natural Killer (NK) Cells: Unlocking NK Cells for Future Immunotherapy;Current Pharmaceutical Biotechnology;2022-03

4. The Important Role of N6-methyladenosine RNA Modification in Non-Small Cell Lung Cancer;Genes;2021-03-19